XLENTI
DEAD

Serial Number

79326685

Owner

Oxford Genetics Ltd

Filing Date

Sep 20, 2021

Add to watchlist:

No watchlists yet
View on USPTO

XLENTI Trademark

Serial Number: 79326685

XLENTI is a trademark filed by Oxford Genetics Ltd on September 20, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Oxford Genetics Ltd (12 trademarks)

Medawar Centre,

Entity Type: 99

Trademark Details

Filing Date

September 20, 2021

Registration Date

Not Registered

Goods & Services

Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal cells and parts thereof for medical and veterinary purposes; microorganisms for medical and veterinary purposes; viral vectors for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use

Chemical and biological substances for use in science and industry; nucleic acids; nucleic recombinant acids, synthetic deoxyribonucleic acids; chemical and biological reagents for non-medical purposes; chemical and biological reagents for scientific and research purposes; human and animal cells and parts thereof for non-medical purposes; microorganisms for non-medical purposes; human and animal cells and parts thereof for scientific and research purposes; microorganisms for scientific and research purposes; viral vectors for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes

Design services relating to the creation and alteration of chemical and biological reagents; design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; design services relating to the creation and alteration of recombinant viruses; design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; research, development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof; design services relating to the creation and alteration of viral vectors; information and advice relating to all the aforesaid services

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Feb 14, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 8, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 22, 2024 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Jan 3, 2024 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 3, 2024 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 16, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 26, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 26, 2023 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 3, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 3, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 3, 2023 ABN2
REFUSAL PROCESSED BY IB
Jul 5, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 14, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 14, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 10, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jun 9, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 7, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 3, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 29, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 25, 2021 REPR